Nephroprotective therapy with angiotensin converting enzyme inhibitors effect evaluation on the course of chronic kidney disease in children with urinary system congenital malformations

The aim: to evaluate the effect of angiotensin-converting enzyme inhibitor (ACEI) therapy on the course of chronic kidney disease (CKD) in children with urinary system congenital malformations.

Patients and methods. 119 patients with urinary system congenital malformations aged 3 to 18 years were examined. A control group of 10 clinically healthy children. There were 3 groups: I - 55 children with congenital vesicoureteral reflex, II - 34 children with congenital hydronephrosis, III - 30 children with other forms of urinary systems dysembryogenesis. ACEI therapy "Enap" ("KRKA", Slovenia), held for 6 months (children up to 14 years at a dose of 0.2 mg/kg/24 h in 1 reception, adolescents 5-10 mg/24 h in 1 reception).

Results. were evaluated according to clinical data, according to the daily monitoring of blood pressure (BP), renal function, renin concentration, plasma aldosterone. Renin and aldosterone production was determined in blood plasma (lying down) by enzyme immunoassay. Results. During ACEI treatment in all children there was stabilization of BP, renal function improvement. Patients with hypertension showed a significant decrease in the concentration of renin. ACEI therapy leads to normalization of aldosterone concentration in patients with hypertension and without hypertension.

Conclusion. The analysis of the course of CKD in patients with US CM on the background of ACEI therapy demonstrates the main aspects of the anti-fibrotic action of the pharmacological blockade of the renin-aldosterone ACEI system.

1. Lysova EV, Savenkova ND. CAKUT-Syndrome in the etiological structure of chronic kidney disease in children and adolescents. Nephrology (Saint-Petersburg) 2017;21(3):69-74 (In Russ.)

2. Komarova O, Tsygin A, Namazova-Baranova L, Baranov A. The rate of different etiology chronic kidney disease progression in children. Nephrology (Saint-Petersburg). 2016; 20(2):53-58 (In Russ.)

3. Smirnov AV. Nacional'nyerekomendacii. National recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. A.V. Smirnov, E.M. SHilov, V.A. Dobronravova et al. Levsha, SPb., 2013; 51 (In Russ.)

4. Nikolaev AYU. Nephroprotective strategy: effect on the progression of chronic kidney disease. In the book.: Treatment of renal failure. Guide for doctors / AYU Nikolaev, YUS Milovanov. Medical information agency, M., 2011; 226-279 (In Russ.)

5. Esayan AM. Tissue renin-angiotensin system of the kidney. New strategy of nephroprotection. Nephrology 2008; 6(3): 8-16 (In Russ.)

6. Morozov DA. Mechanisms of formation and progression of nephrosclerosis in children with vesicoureteral reflux. D.A. Morozov, O.L. Morozova, N.B. Zakharova, D.Y Lakomova. Pediatric surgery 2013; 1: 36-40 (In Russ.)

7. Kuzmin OB. Chronic kidney disease: mechanisms of hypoxic glomerulosclerosis and tubulointerstitial fibrosis development and progression. Nephrology (Saint-Petersburg) 2015;19(4):6-16 (In Russ.)

8. Fedoseev AN. The use of ACE inhibitors to correct endothelial dysfunction in patients at different stages of chronic kidney disease. A.N.Fedoseev, A.S.Kudryakova, V.V.Smirnov i dr. Clinical Nephrology 2012;4:42-45 (In Russ.)

9. Zaicova NM, Dlin VV, Petrovici VG i dr. The effect of angiotensin-converting enzyme inhibitors on urine level of profibrogenic growth factors and morphological changes in the renal parenchyma in rats with infected vesicoureteral reflux. Nephrology (Saint-Petersburg) 2016;20(3):85-95. (In Russ.)

10. Ruster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011; 22 (7): 1189-1199

11. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2159-2219. Doi:10.1093/eurheartj/eht151

12. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2159-2219. Doi: 10.1093/eurheartj/eht151

13. Zorin IV, Vyalkova AA. Prediction of progression of tubulointerstitial damage in children with reflux nephropathy. Nephrology (Saint-Petersburg) 2015;19(3):65-71 (In Russ.)

14. Kostyshina IS. the Role of Central hemodynamic parameters, the thickness of the intima-media complex and endothelial dysfunction in children with renal hypertension. I.S. Kostyshin, O.V. Komarova, A.M. Mazo, T.V. Margieva [et al.] Pediatric pharmacology 2013; 10(3):32-37 (In Russ.)